Physician profile
Hussein Abidali
NPI 1205274768
$4,600.30
in general payments reported to CMS, 2019-2025
19 companies · $2,066 in 2025
The $2,066 reported for 2025 was more than what 80% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $639 · 2020: $453 · 2021: $166 · 2023: $148 · 2024: $1,129 · 2025: $2,066.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,343.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,343.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,622.17 | 2019-2025 | |
| Conmed Corporation | $742.26 | 2019-2021 | |
| Janssen Biotech, INC. | $684.58 | 2024-2025 | Tremfya, Stelara, Simponi |
| Madrigal Pharmaceuticals | $548.15 | 2024-2025 | Rezdiffra, Resmetirom |
| Ardelyx, INC. | $223.20 | 2023-2025 | Ibsrela |
| Gilead Sciences, INC. | $161.66 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $130.33 | 2019-2025 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $84.26 | 2024-2025 | Voquezna |
| Boston Scientific Corporation | $80.63 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.33 | 2019 | |
| Ironwood Pharmaceuticals, INC | $59.44 | 2024 | |
| Ferring Pharmaceuticals INC. | $39.86 | 2024 | Rebyota |
| Intercept Pharmaceuticals, INC. | $29.65 | 2019 | |
| Novo Nordisk INC | $23.35 | 2025 | Wegovy |
| Redhill Biopharma INC. | $23.13 | 2025 | Talicia |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $22.88 | 2024 | Suflave, Sutab |
| Abbott Laboratories | $22.33 | 2024 | Proclaim |
| Olympus America INC. | $22.17 | 2025 | Endoclot Phs |
| Integra Lifesciences Corporation | $19.92 | 2024 | Integra, Primatrix, Integra Dermal Regeneration Template |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hussein Abidali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.